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INTRODUCTION
Although the implantation of coronary stents can prevent
vessels from post-interventional elastic recoil and appears to
limit adverse remodeling, the problem of restenosis and the
need for consecutive reinterventions remains the major lim-
itation of stent implantation (1-3). The mechanism of in-
stent restenosis (ISR) after stent implantation is principally
neointimal hyperplasia (4-8). It has been reported that there
is a strong correlation between the degree of vascular inflam-
mation and neointimal formation (9, 10). The pathological
process of ISR is characterized by an inflammatory healing
process after stretch and damage of the vessel wall (10-12).
Based on observations that ISR is a consequence of inflam-
mation and smooth muscle cell proliferation, several immu-
nosuppressive and anti-proliferative therapies have been inves-
tigated to inhibit these processes. Sirolimus is a potent im-
munosuppressive agent with anti-inflammatory and anti-pro-
liferative effects. Previous studies of sirolimus-eluting stent
(SES) have shown a range of biological effects on inflamma-
tion and neointimal growth (13-15). Paclitaxel suppresses
neointimal formation accompanied by persistent fibrin depo-
sition, macrophage infiltration, and an overall decrease in
smooth muscle cells after implantation (16-18).
Abciximab is a potent inhibitor that block the final path-
way of platelet aggregation and decreases short- and long-
term event rates after percutaneous coronary intervention
(19-21). Besides blocking effect for platelet aggregation,
abciximab reacts to  V 3 receptor of vascular smooth mus-
cle cell and to Mac-1 of macrophage and inhibits prolifera-
tion of vascular smooth muscle cells and inflammatory reac-
tion (22-26). Our previous study showed that abciximab-
coated stent reduced stent restenosis by inhibition of cell
proliferation and extracellular matrix synthesis compared
with bare-metal stent in a porcine coronary restenosis model
(27-29).
We examined the anti-inflammatory effect of abciximab-
coated stent and compared with that of SES and with that
of paclitaxel-eluting stent (PES) in a porcine coronary over-
stretch restenosis model.
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Anti-inflammatory Effect of Abciximab-Coated Stent in a Porcine
Coronary Restenosis Model
The aim of this study was to examine the anti-inflammatory effect of abciximab-coat-
ed stent in a porcine coronary overstretch restenosis model. Ten abciximab-coat-
ed stents, ten sirolimus-eluting stents (SES), and ten paclitaxel-eluting stents (PES)
were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries,
and histopathologic analysis was done at 28 days after stenting. There were no
significant differences in the neointima area normalized to injury score and inflam-
mation score among the three stent groups (1.58± ±0.43 mm
2, 1.57± ±0.39 mm
2 in
abciximab-coated stent group vs. 1.69± ±0.57 mm
2, 1.72± ±0.49 mm
2 in the SES
group vs. 1.92± ±0.86 mm
2, 1.79± ±0.87 mm
2 in the PES group, respectively). In
the neointima, most inflammatory cells were lymphohistiocytes. Significant positive
correlations were found between the extent of inflammatory reaction and the neoin-
tima area (r=0.567, p<0.001) and percent area stenosis (r=0.587, p<0.001). Sig-
nificant correlations were found between the injury score and neointimal area (r=
0.645, p<0.001), between the injury score and the inflammation score (r=0.837,
p<0.001), and between the inflammation score and neointimal area (r=0.536, p=
0.001). There was no significant difference in the inflammatory cell counts normal-
ized to injury score among the three stent groups (75.5± ±23.1/ L in abciximab-
coated stent group vs. 78.8± ±33.2/ L in the SES group vs. 130.3± ±46.9/ L in the
PES group). Abciximab-coated stent showed comparable inhibition of inflammato-
ry cell infiltration and neointimal hyperplasia with other drug-eluting stents in a
porcine coronary restenosis model.
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MATERIALS AND METHODS
Animal study protocol
The animal study was approved by the Ethical Committee
of the Chonnam National University Hospital in Gwangju,
Korea. Study animals were female swine weighing 22-35 kg.
To decrease acute thrombosis after stenting, premedication
with aspirin 100 mg and clopidogrel 75 mg per day was
given for 5 days before procedure. On the day of the stent
implantation, pigs were anesthetized with ketamine (20 mg/
kg intramuscularly) and xylazine (2 mg/kg intramuscularly).
They received 3 L/min of supplemental oxygen continuous-
ly through oxygen mask. After subcutaneous lidocaine 2%
at the cut-down site was administered, left carotid artery was
surgically exposed, and a 7-8F sheath was inserted. Continu-
ous hemodynamic and surface electrocardiographic monitor-
ing was maintained throughout the procedure. After Hep-
arin 10,000 uints was administered intravenously as a bolus
prior to the procedure, the target coronary artery was engaged
using standard 7-8F guide catheters, and control angiograms
of the both coronary arteries were performed using nonionic
contrast agent in two orthogonal views. 
Method of coating abciximab into stents
A plasma polymerization reaction was performed to attach
amine radical to MAC stent (AMG, Munich, Germany) sur-
face. A stent was fixed in tubular reactor, which was made
by pyrex glass tube, and then the pressure was dropped to
less than 5 mtorr by vacuum pump. For attachment of amine
radical to stent surface, diaminocyclohexane monomer was
drifted to tubular reactor a constant dose (0.96 SCCM), and
plasma was generated using at a radiofrequency power gen-
erator. The power for polymerization of plasma was 100 W
for 5 min and then 60 W for 15 min. The used abciximab
is a human-murine chimeric antibody Fab fragment (c7E3
Fab) and blocks glycoprotein IIb/IIIa receptor directly. A 7
cm-long, 1 cm-wide glass tube was boiled in 100℃ water
for 5 min and then taken out and allowed to dry in an incu-
bator. Then 2 mL of abciximab solution was delivered to
this glass tube, and the stent was immersed in this solution.
The carboxy radical of abciximab was introduced to amine
radical attached to stent to achieve covalent bond and im-
proved attachment power between stent and abciximab. This
reaction was performed for 1 hr and then stent was taken out
and allowed to dry for more than 24 hr. For release kinetics
of abciximab from the stent, the stent was placed in glass vial
and immersed in 100 mL of phosphate-buffered saline. We
confirmed coating of abciximab onto the surface of the stent
by scanning electron microscopy. The amount of coating of
abciximab onto the surface of the stent was 90  g/stent, and
the median thickness of coating was 1  m. The amount of
abciximab release to buffer solution was measured using ab-
sorbance test for ultraviolet at 278 nm. The amount of abcix-
imab release increased with the time and remained on the
stent surface 1 month after coating of abciximab to the stent.
Stent- induced stenosis
Besides abciximab-coated stent, we used two commercially
available U.S. Food and Drug Administration-approved
drug-eluting stent platforms Sirolimus (Cypher stent, Cordis,
Johnson and Johnson, Miami Lakes, FL, U.S.A.) and Pacli-
taxel (Taxus stent, Boston Scientific, Boston, MA, U.S.A.).
The used size and length of stents were 3.0×17 mm ab-
ciximab-coated stents, 3.0×18 mm SES, and 3.0×16 mm
PES. The stent was deployed by inflating the balloon to
nominal pressure at injury site, and the resulting stent-to-
artery ratio was 1.3:1. Repeated angiograms were obtained
immediately after stent implantation. Then, all equipments
were removed, and the carotid artery was ligated. All ani-
mals received 100 mg of aspirin and 75 mg of clopidogrel
orally daily until death. Twenty-eight days after stenting,
the animals underwent repeated angiography in the same
orthogonal views before death, and 20 mL of potassium chlo-
ride intracoronary injection was done. The hearts were remov-
ed, and the coronary arteries were pressure-perfusion fixed
at 70 mmHg in 10% neutral-buffered formalin overnight.
Arteries were step-sectioned, processed routinely for light
microscopy, and stained with hematoxylin-eosin stain for
histological analysis.
Histopathological analysis
Histopathologic evaluation of each artery was performed
by an experienced cardiovascular pathologist. The specimens
were embedded in methylmethacrylate, and sections were
cut with the low-speed diamond wafer mounted to the Bue-
hler Isomet saw (Buehler Ltd., Lake Bluff, IL, U.S.A.), leav-
ing the stent wires intact in the cross sections to minimize
potential artifacts from removal of stent wires. Sections of
50- to 100- m thickness were obtained at about 1 mm apart
and stained with hematoxylin-eosin for histological analy-
sis. Measurements of the histopathologic sections were per-
formed using a calibrated microscope, digital video imaging
system, and microcomputer program (Visus 2000 Visual
Image Analysis System, IMT Tech., CA, U.S.A.). Borders
were manually traced for lumen area, area circumscribed by
the internal elastic lamina, and the innermost border of the
external elastic lamina (external elastic lamina area). Mor-
phometric analysis of the neointimal area for a given vessel
was calculated as the measured internal elastic lamina area
minus lumen area. The measurements were made on five
cross-sections from the proximal and distal ends and the
three midpoints of each stented segment. Histopathologic
stenosis was calculated as 100×(1-[lesion lumen area/lesion
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Evaluation of arterial injury
Arterial injury at each strut site was determined by the
anatomic structures penetrated by each strut. A numeric
value was assigned, as previously described by Schwartz et
al.: 0=no injury; 1=break in the internal elastic membrane;
2=perforation of the media; 3=perforation of the external
elastic membrane to the adventitia (30). The average injury
score for each segment was calculated by dividing the sum
of injury scores by the total number of struts at the exam-
ined section. 
Evaluation of inflammation scores and neointimal reaction
With regard to the inflammation score for each individu-
al strut, the grading was as follows: 0=no inflammatory cells
surrounding the strut; 1=light, noncircumferential lympho-
histiocytic infiltrate surrounding strut; 2=localized, moder-
ate to dense cellular aggregate surrounding the strut noncir-
cumferentially; and 3=circumferential dense lymphohistio-
cytic cell infiltration of the strut. The inflammation score
for each cross section was calculated by dividing the sum of
the individual inflammation scores by the total number of
struts at the examined section. Inflammatory cell counts were
normalized to injury score in neointima and compared among
three stent groups.
Statistical analysis
Statistical analysis was performed with the aid of the com-
mercially available software (SPSS Version 11, Chicago, IL,
U.S.A.). The data were presented as mean value±SD. Un-
paired Student’s t test was used for the comparison of inflam-
matory cell counts normalized to injury score of the two
stent groups. Analysis of variance (ANOVA) was used for
comparisons of the three stent groups. To examine the cor-
relations between the measured histologic variables, regres-
sion analysis was applied for each set of measured variables.
A value of p<0.05 was considered statistically significant. 
RESULTS
Procedural characteristics
Two stents were placed for two coronary arteries per one
pig. A total of thirty stents including ten abciximab-coated
setnts, ten SESs, and ten PESs, were placed in the proximal
Fig. 1. The hematoxylin-eosin stain of the low- and high-power fields (magnitude, ×20, ×400) of neointimal hyperplasia and inflammato-
ry cell infiltration in abciximab-coated stent (A, B), sirolimus-eluting stent (C, D), and paclitaxel-eluting stent (E, F). 
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left anterior descending, proximal circumflex, and proximal
right coronary artery for fifteen pigs (Table 1). Mortality for
this study was zero. Quantitative coronary angiography before
and after stent implantation established the stent-to-artery
diameter ratio as 1.336±0.061 for all 30 stented arteries.
There was no significant difference in stent-to-artery ratio
among three stent groups.
Neointimal response to injury 
The lumen area, neointima area, and percent area stenosis
at 28 days after stent implantation were not different signif-
icantly among three stent groups (Fig. 1, Table 2). Although
there was a trend that the average injury score for each seg-
ment was higher in the PES group, this was not statistically
significant (Table 2). There were no significant differences
in the neointima area normalized to injury score and inflam-
mation score among the three stent groups (neointima area
normalized to injury score; 1.58±0.43 mm2 in the abcix-
imab-coated stent group vs. 1.69±0.57 mm2 in the SES
group vs. 1.92±0.86 mm2 in the PES group, and neointi-
ma area normalized to inflammation score; 1.57±0.39 mm2
in the abciximab-coated stent group vs. 1.72±0.49 mm2
in the SES group vs. 1.79±0.87 mm2 in the PES group,
respectively) (Fig. 2).
Neointimal response to inflammation
Although there was a trend that the inflammation score
for each cross-section was higher in the PES group, this was
not statistically significant (Table 2). All the sections exam-
ined revealed various amounts of inflammatory infiltrate sur-
rounding at least one or more of the struts. In neointima,
most inflammatory cells were lymphohistiocytes. The inflam-
matory reaction consisted of groups of pale histiocytic cells
adjacent to the struts with occasional multinucleated giant
cells. A rim of small, dark lymphocytes was also noted at
the periphery, along with fibroblasts and capillaries. In con-
trast, eosinophils and plasma cells were not prominent (Fig.
1). A significant positive correlations were found between
lymphohistiocyte count and the neointimal area (r=0.551,
p=0.001), and between lymphohistiocyte count and percent
area stenosis (r=0.620, p=0.001) (Fig. 3). This correlation
between lymphohistiocyte count and neointimal formation
was similarly observed among three stent groups. Signifi-
cant correlations were found between the injury score and
neointimal area (r=0.645, p<0.001), between the injury
score and the inflammation score (r=0.837, p<0.001), and
between the inflammation score and neointimal area (r=
0.536, p=0.001) (Fig. 4).
Inflammatory reaction according to the stent type, injury
score, and inflammation score
Because there was a strong trend that injury score and in-
Abciximab-
coated stent 
(n=50)
Sirolimus-
eluting stent
(n=50)
Paclitaxel-
eluting stent
(n=50)
p
value
IEL, internal elastic lamina; NS, not significant.
IEL area (mm
2) 19.8±4.4 19.7±5.8 21.7±8.5 NS
Lumen area (mm
2) 17.9±4.1 17.5±5.1 18.9±7.5 NS
Neointima area (mm
2) 1.9±0.8 2.2±1.1 2.8±1.6 NS
% area stenosis  9.6±5.0 11.2±6.0 12.9±8.6 NS
Injury score 1.20±0.40 1.30±0.54 1.46±0.85 NS
Inflammation score 1.21±0.35 1.28±0.47 1.56±0.85 NS
Table 2. Coronary artery morphometric measurements in thirty
stented vessels
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Fig. 2. The neointima area normalized to injury score (A) and inflammation score (B) in the three types of stents.
1.58
1.69
1.92
A
N
e
o
i
n
t
i
m
a
 
a
r
e
a
/
i
n
f
l
a
m
m
a
t
i
o
n
 
s
c
o
r
e
 
(
m
m
2
)
3
2
1
0
Abciximab Sirolimus Paclitaxel
p=NS
1.57
1.72 1.79
B
Abciximab-
coated stent 
(n=10)
Sirolimus-
eluting stent
(n=10)
Paclitaxel-
eluting stent
(n=10)
Left anterior descending artery 4 3 3
Left circumflex artery 2 2 4
Right coronary artery 4 5 3
Table 1. Stented porcine coronary arteries806 Y.J. Hong, M.H. Jeong, S.R. Lee, et al.
flammation score were higher in the PES group and there
was a correlation between the injury score and the inflam-
mation score, we evaluated inflammatory cell infiltration
normalized to the injury score. Although there was a strong
trend that inflammatory cell counts normalized to the injury
score was lower in the abciximab-coated stent group com-
pared to the PES group, this was not statistically significant
(75.5±23.1/ L the in abciximab-coated stent group vs.
78.8±33.2/ L in the SES group vs. 130.3±46.9/ L in the
PES group) (Fig. 5).
DISCUSSION
This study demonstrated that abciximab-coated stent show-
ed comparable anti-inflammatory effect and comparable in-
hibition of neointimal hyperplasia with other drug-eluting
stents in a porcine coronary restenosis model. ISR due to neo-
intimal hyperplasia remains the major limitation of coronary
stents (4-8). There is increasing evidence that inflammation
plays an important role in the initiation and development of
neointimal hyperplasia and subsequent restenosis (9, 10). 
Because of the role of inflammatory cells in restenosis, these
cells seemed to be an optimal target in the fight against res-
Fig. 3. Correlations between the lymphohistiocyte count and (A) neointimal area and (B) percent area stenosis. 
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Fig. 4. Correlations between the injury score and neointimal area (A), between the injury score and the inflammation score (B), and between
the inflammation score and neointimal area (C). 
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Fig. 5. The neointimal inflammatory cell count normalized to injury
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tenosis. The pathological process of ISR is characterized by
an inflammatory healing response after stretch and damage
of the vessel wall. Initially, platelets are activated and attach
around the stent struts followed by adhesion of inflammato-
ry cells. Cytokines and growth factors are released, leading
to smooth muscle cell migration and proliferation (10-12).
Therefore, modulation of the inflammatory response is ex-
pected to decrease ISR. Several immunosuppressive and anti-
proliferative therapies have been investigated to inhibit these
processes (31-35). Recent successes in early clinical trials with
drug-eluting stents using the anti-proliferative agents Siro-
limus (rapamycin) and Paclitaxel (Taxol) have been quite
promising (36-38). 
Our previous study showed that abciximab-coated stent
reduced neointimal hyperplasia by inhibition of neointimal
cell proliferation and extracellular matrix synthesis compared
to bare-metal stent in a porcine coronary restenosis model
(27-29). In our previous study (29), the area of neointima of
abciximab-coated stent was reduced to 45.7% and 45.5%
of the control bare-metal stent at 28 days and 56 days after
stenting, respectively, the content ratio of proteoglycan with-
in the neointima of abciximab-coated stent was reduced to
23% of the control bare-metal stent at 14 days after stent-
ing, the content ratio of collagen within the neointima of
abciximab-coated stent was reduced to 19.7% and 25% of
the control bare-metal stent at 28 days and 56 days after
stenting, respectively, proliferating cell nuclear antigen index
of neointima of abciximab-coated stent was reduced to 22.2%
of the control bare-metal stent at 14 days after stenting, and
the apoptosis of abciximab-coated stent by TUNEL analysis
during a 56-day follow-up after stent implantation was not
different compared to control bare-metal stent. We previ-
ously reported that abciximab-coated stent was feasible and
produced a significant inhibition of neointimal hyperplasia,
showing a potential therapeutic benefit in the prevention of
stent restenosis in human trials (39, 40). In this study, we
suggested that the possible mechanisms responsible for inhi-
bition of neointimal hyperplasia by abciximab might be anti-
platelet, anti-inflammatory, and anti-proliferative actions.
Platelet activation and aggregation induces arterial throm-
bosis and plays a pivotal role in the pathophysiology of acute
coronary syndromes (41, 42). Platelets have been incriminat-
ed in contributing to neointimal hyperplasia via the release
of platelet-derived growth factor that induces smooth mus-
cle cell proliferation and migration. By virtue of the ability
of platelets to facilitate the generation of thrombin, they may
also act as a smooth muscle cell mitogen. Additionally, pla-
telets express multiple counterreceptors for leukocytes, thereby
providing a nidus for vessel wall inflammation.
A glycoprotein II/IIIa receptor blocker, abciximab, is a po-
tent inhibitor that block the final pathway of platelet aggre-
gation and decreases short- and long-term event rates after
percutaneous coronary intervention (19-21). Besides the
blocking effect for platelet aggregation, the blockade of the
glycoprotein IIb/IIIa receptor by abciximab may inhibit the
interaction between platelets and leukocytes, and hence limit
the inflammatory response to coronary intervention. Abcix-
imab cross-reacts and inhibits  V 3. The  V 3 receptor has
also been implicated in neointimal hyperplasia since smooth
muscle cells express  V 3 receptors that are upregulated
further after vascular injury (22). Moreover, in a number of
different animal models, the inhibition of  V 3 receptors
has resulted in decreased neointimal thickening. Abciximab
has cross-reactivity with other integrin receptors, including
Mac-1, which is a major fibrinogen receptor on the polymor-
phonuclear neutrophil surface, and inhibits inflammatory
reaction (23-26). 
In the present study, significant positive correlations were
found between the extent of inflammatory reaction and the
neointimal area and between the extent of inflammatory reac-
tion and percent area stenosis, respectively. Although the
degrees of arterial injury correlated with inflammation score
and neointimal area and there was a trend that injury score
and inflammation score were higher in the PES group, inflam-
matory cell infiltration normalized to injury score was not
different significantly among three stent groups. Thus, abcix-
imab-coated stent might prevent ISR via a comparable anti-
inflammatory effect with other drug-eluting stents.
There are several limitations to be mentioned. Firstly, it
remains to be established whether our findings in normal
nonatherosclerotic porcine coronary arteries stimulated with
oversized stents for neointimal proliferation could be extrap-
olated to human clinical scenarios with preexisting athero-
sclerosis and stent sizes matched to the reference vessel. Sec-
ondly, our study did not examine the early inflammatory
response, as there is little neointimal formation at that time.
Thirdly, although there was a trend toward larger neointima
area in the PES group, injury score also had a trend for increase
in this group, and injury score correlated with inflammation
score and neointimal formation. This may suggest the extent
of injury against intima by overstreching of oversized stent
is related with inflammatory reaction and reactive hyperpla-
sia. Fourthly, although the functional impact of abciximab
might involve the reduced formation of leukocyte-platelet
coaggregates, we did not demonstrate whether abciximab-
coated stent inhibits formation of leukocyte-platelet aggre-
gates. Thus, further studies are needed to demonstrate whether
abciximab-coated stent may inhibit the interaction between
platelets and leukocytes. Fifthly, we did not have a true con-
trol group. We compared different stent designs, lengths,
and polymer drug combinations. Given these model that
induces fairly minimal stenosis, it might not be clear that
we had sufficient numbers to show that there would be a
difference between a true control group and drug-eluting
stents. Sixthly, we examined the histology of inflammation
on H&E stain. It would be more appropriate and accurate
to utilize immunohistochemistry, which is the standard for
these types of studies and with appropriate techniques em-808 Y.J. Hong, M.H. Jeong, S.R. Lee, et al.
ployed on resin-embedded sections.
In conclusion, abciximab-coated stent showed a compara-
ble inhibitory effect for inflammatory cell infiltration and
neointimal hyperplasia with other drug-eluting stents in a
porcine coronary restenosis model. 
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